Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Acta Pharmaceutica Sinica. B|July 29, 2017
Potassium 2-(l-hydroxypentyl)-benzoate attenuates neuroinflammatory responses and upregulates heme oxygenase-1 in systemic lipopolysaccharide-induced inflammation in miceChunyang Zhao, Weizhen Hou, Hui Lei, et al.
Journal of the American Chemical Society|October 11, 2019
Directed Copper-Catalyzed Intermolecular Aminative Difunctionalization of Unactivated AlkenesYang Li, Yujie Liang, Junchao Dong, et al.
Nature Communications|October 22, 2022
Divergent regioselective Heck-type reaction of unactivated alkenes and N-fluoro-sulfonamidesChunyang Zhao, Yang Li, Yujiao Dong, et al.
Clinical Pharmacology in Drug Development|November 1, 2022
A Randomized, Single-dose, Phase I Clinical Comparison of a Trastuzumab Biosimilar With a Reference Trastuzumab Formulation in Healthy Chinese Male VolunteersHuahua Pu, Jingying Jia, Chunyang Zhao, et al.
Diabetes, Obesity & Metabolism|December 2, 2024
Safety, pharmacokinetics and pharmacodynamics of multiple-dose noiiglutide (SHR20004), a novel GLP-1 receptor agonist, in Chinese obese subjects without diabetes mellitusYang Zou, Fan Jiang, Chan Sun, et al.
Materials Today. Bio|May 25, 2026
Tailoring virus-inspired nanoparticles for advanced drug and gene deliveryRuilin Zhou, Miao Xu, Xuting Zheng, et al.
Angewandte Chemie (International Ed. in English)|January 14, 2026
NdO-Intensified Dual-Site Synergy in IrMnO<sub>x</sub> for Acidic Oxygen EvolutionChunyang Zhao, Wei Hu, Chen Cao, et al.
Advanced Materials (Deerfield Beach, Fla.)|April 17, 2025
Fluorine Engineering Induces Phase Transformation in NiCo<sub>2</sub>O<sub>4</sub> for Enhanced Active Motifs Formation in Oxygen Evolution ReactionYa Yue, Xinyu Zhong, Mingzi Sun, et al.
Frontiers in Physiology|September 12, 2022
Polycystin-2 mediates mechanical tension-induced osteogenic differentiation of human adipose-derived stem cells by activating transcriptional co-activator with PDZ-binding motifLiang Wang, Yahui Lu, Guanhui Cai, et al.
Clinical Pharmacology in Drug Development|December 6, 2023
A Randomized, Single-Dose, Parallel-Controlled Phase 1 Clinical Comparison of an Omalizumab Biosimilar Candidate with Reference Omalizumab in Healthy Chinese Male VolunteersJie Cheng, Chenguang Wang, Jin Xu, et al.
Pageof 5